Vitamin D receptor (VDR) mediates the antitumoral action of the active vitamin D metabolite 1a, 25-dihydroxyvitamin D 3 (1,25(OH) 2 D 3 ). VDR expression is lost during colon cancer progression causing unresponsiveness to 1,25(OH) 2 D 3 and its analogs. Previously, Snail1, an inducer of epithelial-to-mesenchymal transition (EMT), was reported to inhibit VDR expression. Here, we show that Snail2/Slug, but not other EMT inducers such as Zeb1, Zeb2, E47 or Twist1, represses VDR gene promoter. Moreover, Snail2 and Snail1 show additive repressing effect on VDR promoter. Snail2 inhibits VDR RNA and protein and blocks the induction of E-cadherin and an adhesive phenotype by 1,25(OH) 2 D 3 . Snail2 reduces the ligand-induced VDR transcriptional activation of a consensus response element and of the CYP24 promoter. Concordantly, Snail2 inhibits the induction of CYP24 RNA and p21 CIP1 , filamin A and vinculin proteins and the repression of c-MYC by 1,25(OH) 2 D 3 . Additionally, Snail2 abrogates b-catenin nuclear export and the antagonism of the transcriptional activity of b-catenin-T-cell factor complexes by 1,25(OH) 2 D 3 . SNAI2 expression is upregulated in 58% of colorectal tumors and correlates inversely with that of VDR. However, VDR downregulation is higher in tumors coexpressing SNAI2 and SNAI1 than in those expressing only one of these genes. Together, these data indicate that Snail2 and Snail1 cooperate for VDR repression in colon cancer.
Introduction
Snail2 (also known as Slug, encoded by Snai2 gene) is a member of the Snail family of zinc finger transcription factors that induce epithelial-to-mesenchymal transition (EMT) (1) . Initially identified as a gene controlling cell migration in the neural crest and developing mesoderm in the chick embryo (2), Snai2 is now believed to favor invasion and metastasis in different types of cancer (1, 3) . Like Snail1, Snail2 represses CDH1/E-cadherin and other epithelial genes and induces the expression of mesenchymal genes in epithelial cells of diverse origin (1, 3, 4) . Accordingly, Snail2 is associated with poor prognosis in breast, ovarian, lung and esophageal squamous cell carcinoma (5) (6) (7) (8) (9) .
Vitamin D receptor (VDR) belongs to the nuclear receptor superfamily of transcription factors and mediates the effects of the active vitamin D metabolite 1a,25-dihydroxyvitamin D 3 (1,25(OH) 2 D 3 ) (10,11). 1,25(OH) 2 D 3 and a number of less calcemic derivatives are in clinical trials as anticancer agents based on their antiproliferative, prodifferentiation, proapoptotic and antimetastatic activity in cultured cells and experimental animal models (12, 13) . We have shown that 1,25(OH) 2 D 3 inhibits proliferation and promotes differentiation of colon cancer cells via the induction of CDH1/E-cadherin and many other genes and by the antagonism of the Wnt/b-catenin pathway that is aberrantly activated in most colon tumors (14, 15) .
Normal colon epithelial cells and some cancer cells express VDR and can synthesize 1,25(OH) 2 D 3 from its precursor. This suggests that the expression of VDR observed in low-grade tumors and the tumorlocalized production of the hormone could be an autocrine or paracrine mechanism to control tumor progression (16, 17) . Concordantly, VDR expression is considered a favorable prognosis marker in colorectal cancer (18, 19) . However, VDR expression is downregulated during colon cancer progression causing ligand unresponsiveness and failure of therapy with 1,25(OH) 2 D 3 and its analogs (16, 17, 20) . Previously, we reported that the transcription factor Snail1 binds to three E-boxes (CAGGTG) in the human VDR gene proximal promoter and represses its expression (21) . Human colon cancer cells ectopically expressing Snail1 became resistant to growth inhibition by the 1,25(OH) 2 D 3 analog EB1089 when they were injected subcutaneously in immune-deficient mice. In humans, we found SNAI1 RNA expression in 60-70% of colon tumors and a significant inverse correlation between the expression of SNAI1 and that of VDR (21, 22) . Furthermore, loss of VDR is linked to tumor dedifferentiation and CDH1/E-cadherin downregulation (22) .
As VDR downregulation cannot be explained by SNAI1 overexpression in a subset (20%) of human colorectal cancers (21, 22) , we have now examined whether other genes that induce EMT inhibit VDR expression. We report here that Snail2, but not Zeb1, Zeb2, E47 or Twist1, inhibits VDR gene promoter activity and decreases VDR RNA and protein expression. The repressive effect is mediated by the three E-boxes present in the VDR promoter previously described to bind Snail1. Retrovirus-mediated stable expression of Snail2 blocks VDR expression and the effects of 1,25(OH) 2 D 3 in human SW480-ADH colon cancer cells: the induction of p21 CIP1 , CDH1/E-cadherin and other target genes and the adhesive phenotype, the repression of c-MYC and the interference with the Wnt/b-catenin pathway. Supporting a role of Snail2 in VDR downregulation during colon cancer progression, we have found a significant inverse correlation between SNAI2 and VDR RNA levels in human colorectal tumors. Importantly, SNAI2 RNA expression is higher in SNAI1-expressing tumors, and Snail2 and Snail1 collaborate in the repression of VDR gene in cultured cells and human tumors.
Materials and methods

Cell culture
Human SW480-ADH, HCT116, CaCo2, LS174T and HT29 colon adenocarcinoma cell lines and HEK293T cells were maintained in Dulbecco's modified Eagle's medium containing 10% fetal bovine serum and 2 mM L-glutamine (all from Invitrogen, Paisley, UK). SW480-ADH cells are a subpopulation derived from SW480 cell line and show an adhesive phenotype, express substantial VDR levels and are thus responsive to 1,25(OH) 2 D 3 (14) . All experiments using 1,25(OH) 2 D 3 (supplied by Drs R.Bouillon and M.Verstuyf, University of Leuven, Belgium; J.P.Van de Velde, Solvay-Duphar, Weesp, The Netherlands and M.Uskokovic, Hoffmann-La Roche Pharmaceuticals, Nutley, NJ) were performed in Dulbecco's modified Eagle's medium supplemented with charcoal-treated serum to remove liposoluble hormones. Cells were treated with 100 nM 1,25(OH) 2 D 3 or the corresponding vehicle/isopropanol concentration for the indicated times. Phase-contrast images were captured with a DC300 digital camera (Leica, Wetzlar, Germany) mounted on an inverted Leitz Labovert FS microscope and processed using Adobe Photoshop software (Adobe Systems, San José, CA).
Generation of stable cell lines SW480-ADH cells stably expressing Snail2 (Snail2 cells) or an empty vector (Mock cells) were generated by retroviral transduction. We cloned the entire mouse Snai2 complementary DNA tagged at the 3#-end with the sequence encoding the hemagglutinin (HA) epitope into the EcoRI/XhoI sites of the pRV-IRES-green fluorescent protein (GFP) retroviral vector to generate the pRV-Snai2-IRES-GFP vector. To obtain the retroviral supernatant, HEK293T cells were cotransfected using calcium phosphate with the retroviral vector (pRV-IRES-GFP or pRV-Snai2-IRES-GFP) and the expression vectors for the retroviral proteins Gag, Pol and Env, and the medium containing retroviral particles was collected two days after transfection. SW480-ADH cells were infected for 8 h with the retroviral supernatant (pRV-IRES-GFP for Mock cells and pRV-Snai2-IRES-GFP for Snail2 cells) and then cultured for additional 72 h. Transduced (GFP-positive) cells were sorted using an Epics Altra Cell Sorting System (Beckman Coulter, Fullerton, CA). Experiments were performed with Mock and Snail2 cells obtained in three independent transduction experiments that rendered similar levels of GFP and/or Snail2 overexpression.
Patients and tumor samples
We recruited 98 patients diagnosed as bearing colorectal cancer and included them in a study approved by the Research Ethics Board of Hospital Universitario Puerta de Hierro. Patients were considered sporadic cases because no clinical antecedents of familial adenomatous polyposis were reported and those with clinical criteria of hereditary non-polyposis colorectal cancer (Amsterdam criteria) were excluded. Normal and tumor tissue samples were obtained immediately after surgery, immersed in RNA later (Applied Biosystems, Carlsbad, CA), snap-frozen in liquid nitrogen and stored at À80°C until processing. All patients of the study gave written informed consent. All tumors were examined by a pathologist to confirm the diagnosis of adenocarcinoma, select those samples with .75% neoplastic cells and establish the histological grade. The following clinicopathological parameters were obtained from the medical records of the 98 patients: age, gender, tumor localization, histological grade, pathological stage, presence of lymph node metastases and vascular invasion.
Reporter assays
We used reporter plasmids containing the Firefly luciferase gene (Luc) under the control of the following: the À600/þ23 fragment of the human VDR gene promoter, wild-type or mutated in three E-box sequences (MUT) (21) ; the À178/þ92 fragment of the human CDH1/E-cadherin gene promoter, wild-type or MUT (23) ; the À367/þ1 fragment of the CYP24 gene promoter (a gift from Dr A.Aranda from our Institute); four tandem copies of a consensus DR3 vitamin D response element (VDRE) cloned upstream of the herpes simplex virus tk gene promoter (a gift from Dr C.Carlberg, University of Luxembourg, Luxembourg) and four multimerised copies of wild-type (TOP-Flash) or MUT (FOP-Flash) T-cell factor (TCF)/LEF-binding sites upstream of a minimal c-fos promoter (a gift from Dr H.Clevers, Hubrecht Laboratory, Utrecht, The Netherlands). In addition, we used the pRLSV40 plasmid (Promega, Madison, WI) containing the Renilla reniformis luciferase gene (RLuc) under the control of the SV40 virus promoter as a control. The expression vectors for mouse Snail1, Snail2 and E47 cloned in pcDNA3 were gifts from Dr A.Cano of our Institute. The expression vectors of mouse Zeb1 and for human VDR, ZEB2 and TWIST1 cloned in pcDNA3 have been described previously (24, 25) . Cells were transfected using the jetPEI transfection reagent (PolyPlus Transfection, Illkirch, France) and 200 ng of Luc vectors, 10 ng of RLuc vector and 50 ng (or the amount indicated) of expression vectors. Cells were harvested 48 h later for analysis of luciferase activities. In the indicated cases, cells were treated 24 h after transfection with 1,25(OH) 2 D 3 or vehicle for additional 10 or 48 h and then harvested to measure luciferase activities. Analysis of Luc and RLuc activities was performed using the Dual Luciferase Reporter Assay System (Promega) and a Lumat LB9507 luminometer (Berthold, Bad Wildbad, Germany). The Luc activity was then normalized to RLuc activity.
Western blotting
Cells were lysed in sodium dodecyl sulfate buffer (25 mM Tris-HCl pH 7.6, 1 mM ethylenediaminetetraacetic acid, 1 mM ethyleneglycol-bis(aminoethylether)-tetraacetic acid and 2% sodium dodecyl sulfate) supplemented with 1 mM ortovanadate, 1 mM phenylmethylsulfonyl fluoride, 10 lg/ml leupeptin and 10 lg/ml aprotinin. Lysates were sonicated in a Bioruptor (Diagenode, Liège, Belgium), centrifuged at 13 000 r.p.m. for 10 min at 4°C and supernatants were conserved at À80°C. For immunoblotting, cell lysates were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and proteins were then transferred to polyvinylidene difluoride membranes (Pall Corporation, East Hills, NY). Membranes were incubated with primary and secondary antibodies, and antibody binding was visualized using the enhanced chemiluminescence detection system (GE Healthcare, Chalfont St Giles, UK).
The antibodies used were: E-cadherin (BD Biosciences, San Jose, CA); VDR and p21 CIP1 (Millipore, Billerica, MA); HA (Covance, Princeton, NJ); filamin A (Research Diagnostic, Flanders, NJ); c-MYC, vinculin, b-actin and horseradish peroxidase-conjugated anti-rat immunoglobulin G (IgG) and anti-goat IgG (Santa Cruz Biotechnology, Santa Cruz, CA) and horseradish peroxidaseconjugated anti-mouse IgG (Promega). Films were scanned with a SNAPSCAN e42 (AGFA, Mortsel, Belgium) and images were processed using Adobe Photoshop software. Quantification was done by densitometry using ImageJ software. b-Actin was used for normalization.
Immunofluorescence analysis Cells were rinsed in phosphate-buffered saline (PBS) and fixed by two methods: with cold methanol for 1 min (for E-cadherin, b-tubulin and b-catenin staining) or with 3.7% paraformaldehyde for 15 min (for b-actin staining). In the case of paraformaldehyde fixation, cells were then permeabilized with 0.5% Triton and washed in PBS. Non-specific sites were blocked by incubation with PBS containing 1% goat serum for 30 min at room temperature and then the cells were incubated with the primary antibodies diluted in PBS overnight at 4°C. After four washes in PBS, cells were incubated with secondary antibodies for 1 h at room temperature and washed. Antibodies used were E-cadherin and b-catenin (BD Biosciences), b-tubulin (Sigma-Aldrich, St Louis, MO) and Alexa488-conjugated anti-mouse IgG (Jackson ImmunoResearch Europe, Suffolk, UK). For b-actin staining, cells were incubated with tetramethyl rhodamine iso-thiocyanate-conjugated phalloidin (Sigma-Aldrich) for 15 min at room temperature and washed in PBS. Finally, the coverslips containing the cells were mounted on glass slides using Prolong (Invitrogen). Confocal microscopy was performed with a TCS SP5 DMI6000 spectral confocal microscope (Leica) using argon ion (488 nm) and HeNe (532 nm) lasers. Images were acquired using Leica Confocal software and processed using Adobe Photoshop software.
RNA extraction and quantitative reverse transcription-polymerase chain reaction RNA was extracted from $30 mg of tumor or normal tissue and from cultured cells using RNeasy Mini Kit (Qiagen, Hilden, Germany). The level of CDH1/Ecadherin, VDR, SNAI2 and SNAI1 RNA was measured by quantitative reverse transcription-polymerase chain reaction (qRT-PCR) in relation to that of the housekeeping gene succinate dehydrogenase complex subunit A (SDHA) using the standard curve method (21) . RNA was retrotranscribed using the Gold RNA PCR Core Kit (Applied Biosystems). The quantitative PCR reaction was performed in a LightCycler using the LightCycler-FastStart PLUS DNA Master SYBR Green I Kit (both from Roche, Basel, Swizerland). Thermal cycling consisted of a denaturing step at 95°C for 10 min and 40 cycles of denaturing at 94°C 0 s; annealing at 68°C (SNAI1), 60°C (CDH1 and VDR) or 59°C (SNAI2 and SDHA) for 5 s and elongation at 72°C for 5 s. Oligonucleotides for CDH1, VDR, SNAI1 and SDHA were described previously (21) , and those for SNAI2 were: sense 5#-GGCAAGGCGTTTTCCAGAC-3# and antisense 5#-GCTCTG-TTGCAGTGAGGGC-3#. The level of CYP24 RNA was measured by qRT-PCR in relation to that of 18S ribosomal RNA using the comparative C t method and RNA TaqMan probes (Applied Biosystems). RNA was retrotranscribed using the High-Capacity cDNA Archive Kit (Applied Biosystems). The quantitative PCR reaction was performed in an ABI Prism 7900 HT thermal cycler using TaqMan Gene Expression Master Mix (both from Applied Biosystems). Thermal cycling consisted of a denaturing step at 95°C for 10 min and 40 cycles of denaturing at 95°C for 15 s and annealing and elongation at 60°C for 60 s.
Statistical analysis
Statistical significance was assessed by two-tailed unpaired Student's t-test using the GraphPad InStat3 software (San Diego, CA) unless otherwise indicated. Differences were considered statistically significant when P , 0.05. The single asterisk ( Ã ) indicates P , 0.05, the double asterisk ( ÃÃ ) P , 0.01 and the triple asterisk ( ÃÃÃ ) P , 0.001. P . 0.05 was considered not significant. The correlation between the tumor versus normal ratio (T:N) of SNAI2 RNA expression and that of VDR in samples from colon cancer patients was studied using the Spearman correlation coefficient. Since SNAI1 RNA was not detected in any normal tissue, the T:N cannot be calculated and its expression was evaluated as presence or absence in tumor tissue. Therefore, correlation between SNAI1 tumor expression and T:N of SNAI2 or VDR expression was studied using Kruskal-Wallis test. Human samples were divided into four groups according to the tumor expression of SNAI1 (presence or absence) and that of SNAI2 (T:N , 1 or T:N . 1). Kruskal-Wallis test was also used to study VDR T:N expression within the four groups. Associations between clinicopathological parameters and gene expression were studied with Kruskal-Wallis (for quantitative gene expression data) or v 2 (for qualitative gene expression data) tests. Statistical analysis of gene expression data from colon cancer patients was performed using SPSS software (SPSS, Chicago, IL). Differences were considered statistically significant when P , 0.05. P . 0.05 was considered not significant (ns).
Results
Snail2, but not other EMT inducers, represses VDR gene promoter
To investigate whether the repression of the human VDR gene is specific of Snail1 or a common action of other EMT inducers, we studied the effect of Snail2, Zeb1, Zeb2, E47 and Twist1 on VDR promoter activity. Only Snail2 inhibited VDR proximal promoter (À600/þ23) activity in transfected SW480-ADH cells that harbor mutated APC, K-RAS and TP53 genes ( Figure 1A ). The effect was quantitatively similar to that of Snail1 and was also dependent on the three E-boxes present in the VDR promoter as it was abolished by their triple mutation (MUT construct) ( Figure 1B) .
To examine the possibility of a coordinated action of Snail2 and Snail1, the cells were then cotransfected with their expression vectors alone or in combination. The two genes collaborated to repress VDR promoter showing an additive effect ( Figure 1C) . Next, the repression of VDR promoter by Snail2 was validated in four additional human colon cancer cell lines that harbor variable panels of mutations frequently found in colon tumors: HCT116 (K-RAS, CTNNB1/b-catenin, CDKN2A), CaCo2 (APC, CTNNB1/b-catenin, TP53), LS174T (K-RAS, CTNNB1/b-catenin, CDH1/E-cadherin) and HT29 (APC, B-RAF, TP53) ( Figure 1D ). qRT-PCR studies confirmed the increased expression of Snai2 RNA in Snail2 cells and showed that Snail2 expression significantly reduced VDR RNA levels ( Figure 3A) . As control of the activity of the ectopic protein, Snail2 cells contained much lower CDH1/E-cadherin RNA than Mock cells ( Figure 3A) . Consistently, the activity of VDR (À600/þ23) and CDH1/E-cadherin (À178/þ92) proximal promoters was lower in Snail2 than in Mock cells ( Figure 3B ). In line with the immunofluorescence analysis ( Figure 2B , upper panels), the increase of CDH1/E-cadherin RNA induced by 1,25(OH) 2 D 3 was strongly reduced in Snail2 cells ( Figure 3C ). Likewise, western blot analysis showed a strong reduction of E-cadherin protein levels in 1,25(OH) 2 D 3 -treated Snail2 cells as compared with Mock cells (Figure 3D ). In addition, Snail2 cells expressed significantly less VDR protein than Mock cells in the absence and presence of 1,25(OH) 2 D 3 ( Figure 3D ). As VDR RNA levels did not change after 1,25(OH) 2 D 3 treatment in SW480-ADH cells (data not shown), the slight increase of VDR protein found in 1,25(OH) 2 D 3 -treated cells must be consequence of the reported ligand effects on VDR protein stability (26) .
Snail2 inhibits ligand-induced VDR transcriptional activity Next, we examined the effect of Snail2 on VDR transcriptional activity. First, the activation of a consensus VDRE by 1,25(OH) 2 D 3 was studied in Mock and Snail2 cells. The activation was strongly reduced Figure 5B and C) . Unexpectedly, we also found that Snail2 overexpression reduces c-MYC levels ( Figure 5B ).
As Snail1 impedes the antagonistic effect of 1,25(OH) 2 D 3 on the Wnt/b-catenin-signaling pathway (25), we studied the putative action of Snail2. Immunofluorescence analyses showed that the relocation of b-catenin protein from the cell nucleus to the plasma membrane induced by 1,25(OH) 2 D 3 in Mock cells did not take place in Snail2 cells ( Figure 5D ). Consistently, the repression of b-catenin/TCF transcriptional activity (final downstream step of the Wnt/b-catenin pathway) by 1,25(OH) 2 D 3 was not observed in Snail2 cells ( Figure  5E ) or in SW480-ADH cells transiently transfected with Snail2 (Figure 5F ). Indicating the importance of VDR repression for this effect, exogenous VDR partially restored the inhibition of b-catenin/TCF transcriptional activity in cells overexpressing Snail2 ( Figure 5E and F).
The expression of SNAI2 and VDR correlate inversely in human colorectal tumors Finally, we explored the expression of SNAI2 and VDR RNA in normal and tumor tissue of colon cancer patients by qRT-PCR. Variable expression of the two genes was detected in all 98 matched tumor and normal tissues studied. SNAI2 was expressed at higher level in tumor versus normal tissue (T:N . 1) in 58% of patients, whereas VDR was downregulated (T:N , 1) in 64%. Consistently with data obtained in cultured cells, we found a statistically significant inverse correlation between SNAI2 and VDR RNA levels (Spearman correlation coefficient r 5 À0.302, P 5 0.003) 
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( Figure 6A ). We also analyzed SNAI1 expression in the same biopsies. In line with previous studies (21, 22) , SNAI1 expression was found in 59% of tumors and it correlated with VDR downregulation (KruskalWallis test, P , 0.001). We did not detect SNAI1 expression in any normal tissue. Of note, we found that SNAI2 expression was significantly higher in tumors expressing SNAI1 [the median of SNAI2 T:N expression was 0.75 (log 10 0.75 5 À0.12) in SNAI1-negative tumors versus 1.56 (log 10 1.56 5 0.19) in SNAI1-positive tumors; KruskalWallis test, P 5 0.001] ( Figure 6B ). We analyzed VDR expression in tumors expressing neither, either or both SNAI genes ( Figure 6C ). VDR levels in tumors that only express SNAI2 were similar to those found in SNAI1-and SNAI2-negative tumors. Tumors that express SNAI1 but not SNAI2 showed lower VDR levels than tumors negative for both genes, although the data did not reach statistical significance. Remarkably, VDR downregulation was significantly higher in the tumors expressing both transcription factors (42% of colon tumors) (Kruskal-Wallis test) ( Figure 6C) . Analysis of the clinicopathological parameters of the patients confirmed the previously published (22) significant associations between VDR downregulation and tumor dedifferentiation (Kruskal-Wallis test, P 5 0.014) and between SNAI1 expression and presence of vascular invasion (v 2 test, P 5 0.026). Previous work by our group and others had reported the inhibition of VDR by Snail1 in human colon cancer and in mouse osteoblasts (21, 28) . Our results now show that the repression of VDR is a specific effect of the Snail family members Snail1 and Snail2 that is not shared by other EMT inducers such as Zeb1, Zeb2, E47 and Twist1. This suggests that although all these transcription factors repress E-cadherin and activate EMT, they are not redundant. Accordingly, other studies suggest that the partially different gene expression profiles induced by Snail1, Snail2 and E47 confer them a specific role in the EMT process (29) . The shared repression of VDR by Snail1 and Snail2 indicates its importance for the induction of EMT by these factors at least in colon cancer. As ligand-activated VDR induces epithelial differentiation and the expression of E-cadherin and other intercellular adhesion genes (11, 14, 15) , VDR repression by Snail proteins guarantees the induction of EMT even in the presence of 1,25(OH) 2 D 3 . Snail1 and Snail2 have other targets in common such as CDH1/E-cadherin, CLDN1/claudin-1 and OCLN/occludin (23, (30) (31) (32) (33) (34) (35) .
The expression of SNAI1 and SNAI2 in human colon is not identical. As previously reported (21, 22) and now confirmed, SNAI1 RNA is absent in normal colon tissue and is upregulated in 60-70% of colon tumors. As Roy et al. (36) found SNAIL1 protein expression in 78% of colon tumors, SNAIL1 RNA and protein expression seems to correlate in colon cancer. In contrast, we now show that SNAI2 RNA is expressed in both normal and tumor tissue, with overexpression in 58% tumors. Shioiri et al. (37) found SNAIL2 protein expression in 37% colon tumors. However, the authors stated that the protein was mainly localized in the cytoplasm, where it cannot exert its gene repressive activity. Thus, there must be either unspecific staining or nonfunctional SNAIL2 protein. Unfortunately, the lack of antibodies against SNAIL2 of sufficient specificity precludes an appropriate study of the putative differences between SNAIL2 RNA and protein levels in colon cancer.
VDR downregulation was significantly stronger in colon tumors that are positive for SNAI1 and overexpress SNAI2 than in those that express only one of these genes. This is consistent with the strong additive effect exerted by Snail2 and Snail1 on VDR gene promoter in SW480-ADH cells. Therefore, Snail2 and Snail1 seem to collaborate to repress VDR expression. In addition, we found that SNAI2 RNA levels were higher in SNAI1-positive than in SNAI1-negative tumors. This contributes to explain the high proportion of tumors (42%) that express both transcription factors and is concordant with reports in other systems that suggest cross-regulation between Snail1 and Snail2 (38) (39) (40) . Since Snail2 is target of b-catenin-signaling pathway (41), the increase of SNAI2 in SNAI1-positive tumors may be consequence of the reported activation of this pathway by Snail1 (42, 43) . In addition, these data may indicate that Snail2 could enhance and/or extend the repression of VDR exerted by Snail1, playing a similar role to that proposed for Zeb1 (another Snail1 downstream effector) on CDH1/ E-cadherin expression (1, 44) .
Our results are consistent with the collaboration found between Snail1 and Snail2 on tumor growth and metastasis properties of mouse skin carcinoma cells (45) . The latter authors proposed a hierarchical participation of both factors in the metastatic process with a major regulatory role of Snail1 on local invasiveness. Mouse Snail1 and Snail2 also have distinct roles and collaborate in the induction of invasiveness in SKOV3 ovarian carcinoma cells (46) . Furthermore, SNAI2 RNA is overexpressed in 58% of gastric cancers, in a statistically significant direct association with SNAI1 RNA level in diffusetype gastric carcinomas (40) .
Recently, the human SNAIL2 protein has been found to bind and repress the VDR promoter in MCF7 and MDA-MB-468 breast cancer cell lines, although the authors performed neither functional analysis nor studies in tumors (47) . Our data in cultured cells show that Snail2 or Snail1 alone represses VDR expression with similar potency. However, in human colon cancer biopsies, VDR is only significantly downregulated in tumors that express both transcription factors. Therefore, the expression of Snail1 or Snail2 alone seems to have lower effect on VDR level in tumors than in colon cancer cell lines. Our data also reveal that the expression of SNAIL1 alone in tumors has a repressive effect on VDR expression that perhaps would reach statistical significance in a larger series of tumors, whereas that of SNAIL2 does not. There are several possible explanations for this apparent discrepancy between data from human biopsies and cell lines. One is the existence of other factors in human colon tumors that can modulate SNAIL1 and SNAIL2 activity. Thus, the inverse correlation between SNAI1 and VDR RNA is lost in tumors that express high levels of the transcriptional coregulators p300 and CtBP (48) . Another putative explanation is that the level of Snail2 or Snail1 proteins achieved in cultured cells by stable or transient transfection may be higher than that found in human tumors, overpassing a certain threshold that allows each of them to repress VDR by itself.
Our results predict that colon cancer patients with high levels of SNAIL1 and SNAIL2 will have lower VDR expression and, therefore, will be poor responders to therapy with 1,25(OH) 2 D 3 or its analogs. As with other therapies, it is important to select those patients that are probably to respond, and thus, tumor expression of SNAIL1 and SNAIL2 may be used as indicator of adequacy. In the last years, several groups have detected tumor-associated RNA in the serum/ plasma of cancer patients (49) . If tumor overexpression of SNAI1 and SNAI2 could be monitorized by reverse transcription-PCR analysis of the RNA present in the serum/plasma, it would constitute a non-invasive method to select suitable patients for therapy with 1,25(OH) 2 D 3 or its analogs.
In conclusion, this study indicates that Snail2 is a repressor of VDR and thereby of 1,25(OH) 2 D 3 action in cultured colon cancer cells and that human SNAIL2 and SNAIL1 collaborate to repress VDR expression in colorectal tumors. 
